Independent risk factors for COVID-19-associated coagulopathy

被引:0
作者
Tor, Y. B. [1 ]
Ozbalak, M. [2 ]
Kalayoglu-Besisik, S. [2 ]
Aksoy, E. [1 ]
Cagatay, A. A. [3 ]
Gul, A. [4 ]
Erelel, M. [5 ]
Senkal, N. [1 ]
Medetalibeyoglu, A. [1 ]
Kose, M. [1 ]
Tukek, T. [1 ]
机构
[1] Istanbul Univ, Dept Internal Med, Istanbul Fac Med, Istanbul, Turkiye
[2] Istanbul Univ, Div Hematol, Dept Internal Med, Istanbul Fac Med, Istanbul, Turkiye
[3] Istanbul Univ, Dept Infect Dis & Clin Microbiol, Istanbul Fac Med, Istanbul, Turkiye
[4] Istanbul Univ, Div Rheumatol, Dept Internal Med, Istanbul Fac Med, Istanbul, Turkiye
[5] Istanbul Univ, Dept Chest Dis, Istanbul Fac Med, Istanbul, Turkiye
关键词
COVID-19; Inflammation; Lactate dehydrogenase; Low molecular weight heparin; Thrombosis;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: Past three years since the beginning of the outbreak, we have obtained satisfactory data on COVID-19. However, data on risk factors of COVID-19-associated coagulopathy (CAC) are extremely limited. Prediction of CAC might be a game changer since it is related to poor prognosis. Seeking independent risk factors for CAC was the main aim of the study. PATIENTS AND METHODS: 510 hospitalized COVID-19 patients were retrospectively screened. Forty-eight of them were excluded due to irrelevant D-dimer or ferritin elevation. The remaining patients were stratified into three groups as overt coagulopathy, significant pulmonary microthrombosis, and patients without coagulopathy. The overt coagulopathy group included cases with macrothrombosis or disseminated intravascular coagulation (DIC). The significant pulmonary microthrombosis group covered the cases that had clinical deterioration with simultaneous marked D-dimer elevation. The group of patients without coagulopathy included the asymptomatic patients with normal or elevated D-dimer levels. RESULTS: Overt coagulopathy developed in 3.2% and significant pulmonary microthrombosis in 10.1% of the patients. In the multivariate analysis, not receiving low molecular weight heparin ( LMWH) (p=0.002) and a level of D-dimer >15,000 U/ml (p=0.013) were associated with overt coagulopathy. In addition, levels of initial LDH >480 IU/L (p=0.022), initial ferritin >1,000 ng/ml (p=0.036) were associated with significant pulmonary microthrombosis. Not receiving LMWH (p=0.001) was also associated with significant pulmonary microthrombosis, when multivariate analysis was performed by the parameters with a p-value <0.1 in the univariate analysis. Furthermore, all cases with DIC had Gram-negative bacterial sepsis. CONCLUSIONS: Not receiving LMWH, high levels of D-dimer, initial LDH, and initial ferritin are independent risk factors for CAC. DIC does not appear to develop based on COVID-19.
引用
收藏
页码:7851 / 7860
页数:10
相关论文
共 50 条
[31]   COVID-19-associated coagulopathy and antithrombotic agents-lessons after 1 year [J].
Leentjens, Jenneke ;
van Haaps, Thijs F. ;
Wessels, Pieter F. ;
Schutgens, Roger E. G. ;
Middeldorp, Saskia .
LANCET HAEMATOLOGY, 2021, 8 (07) :e524-e533
[32]   Understanding COVID-19-associated coagulopathy: From PIC to SIC or DIC [J].
Wang, Zhong ;
Gao, Xiang ;
Miao, He ;
Ma, Xiaochun ;
Ding, Renyu .
JOURNAL OF INTENSIVE MEDICINE, 2021, 1 (01) :35-41
[33]   Cerebral venous thrombosis in COVID-19-associated coagulopathy: A case report [J].
Sugiyama, Yohsuke ;
Tsuchiya, Takaaki ;
Tanaka, Ryota ;
Ouchi, Aiko ;
Motoyama, Arata ;
Takamoto, Takeshi ;
Hara, Natsumi ;
Yanagawa, Yoshitaka .
JOURNAL OF CLINICAL NEUROSCIENCE, 2020, 79 :30-32
[34]   COVID-19-associated coagulopathy: thromboembolism prophylaxis and poor prognosis in ICU [J].
Runhui Zheng ;
Jing Zhou ;
Bin Song ;
Xia Zheng ;
Ming Zhong ;
Li Jiang ;
Chun Pan ;
Wei Zhang ;
Jiaan Xia ;
Nanshan Chen ;
Wenjuan Wu ;
Dingyu Zhang ;
Yin Xi ;
Zhimin Lin ;
Ying Pan ;
Xiaoqing Liu ;
Shiyue Li ;
Yuanda Xu ;
Yimin Li ;
Huo Tan ;
Nanshan Zhong ;
Xiaodan Luo ;
Ling Sang .
Experimental Hematology & Oncology, 10
[35]   Relationship between Covid-19-associated pneumonia severity with coagulopathy and mortality [J].
Avci, Begum Seyda ;
Kaya, Adem ;
Sumbul, Hilmi Erdem ;
Icme, Ferhat ;
Yesilagac, Hasan ;
Unal, Nevzat ;
Yesiloglu, Onder ;
Cinar, Hayri ;
Turunc, Tuba .
CUKUROVA MEDICAL JOURNAL, 2021, 46 (02) :540-547
[36]   COVID-19: a probable role of the anticoagulant Protein S in managing COVID-19-associated coagulopathy [J].
Chatterjee, Sabyasachi ;
Sengupta, Tanusree ;
Majumder, Samarpan ;
Majumder, Rinku .
AGING-US, 2020, 12 (16) :15954-15961
[37]   Divergent impacts of tocilizumab and colchicine in COVID-19-associated coagulopathy: the role of alpha-defensins [J].
Abdeen, Suhair ;
Abu-Fanne, Rami ;
Bdeir, Khalil ;
Maraga, Emad ;
Higazi, Mohamed ;
Cines, Douglas B. ;
Heyman, Samuel N. ;
Higazi, Abd Al-Roof .
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 196 (04) :923-927
[38]   Report of the ISTH registry on pregnancy and COVID-19-associated coagulopathy (COV-PREG-COAG) [J].
Kazi, Sajida ;
Othman, Maha ;
Khoury, Rasha ;
Bernstein, Peter S. ;
Thachil, Jecko ;
Ciantar, Etienne ;
Ferrara, Laura ;
Netto, Manju ;
Abdul-Kadir, Rezan ;
Malinowski, A. Kinga .
OBSTETRIC MEDICINE, 2024, 17 (01) :13-21
[39]   The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic thrombocytopenia [J].
Iba, Toshiaki ;
Levy, Jerrold H. .
TRENDS IN CARDIOVASCULAR MEDICINE, 2022, 32 (01) :1-9
[40]   COVID-19-associated coagulopathy and unfavorable obstetric outcomes in the third trimester of pregnancy [J].
Cetera, Giulia E. ;
D'Ambrosi, Francesco ;
Iurlaro, Enrico ;
Cesano, Nicola ;
Carbone, Ilma F. ;
De Marinis, Stefano ;
Ferrazzi, Enrico .
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2022, 157 (01) :206-207